The progress in HCV therapy in the last three years is similar to the progress that took HIV therapy ∼14 years. We are at the brink of approval for an all-oral drug combination that is dosed once daily as a single pill, has >95% efficacy, and is well tolerated. This article summarizes the path to this success and the challenges still ahead.
No takes yet. Share an insight, caveat, or question.
Ann D. Kwong (2014) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: